EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update, Eur Urol, vol.64, pp.639-53, 2013. ,
Bladder cancer incidence and mortality: a global overview and recent trends, Eur Urol, vol.71, pp.96-108, 2017. ,
The present and future burden of urinary bladder cancer in the world, World J Urol, vol.27, pp.289-93, 2009. ,
Surgical advances in bladder cancer: at what cost?, Urol Clin North Am, vol.42, pp.235-52, 2015. ,
ESMO practice guidelines for diagnosis, treatment and follow-up, Ann Oncol, vol.25, issue.3, pp.40-48, 2014. ,
Recurrence and progression of disease in non-muscle-invasive bladder cancer: from epidemiology to treatment strategy, Eur Urol, vol.56, pp.430-472, 2009. ,
CCAFU french national guidelines 2016-2018 on bladder cancer, Progres En Urol, vol.27, issue.1, pp.67-91, 2016. ,
Chemotherapy for metastatic or unresectable bladder cancer, Semin Oncol, vol.34, pp.135-179, 2007. ,
Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract, J Clin Oncol, vol.27, pp.4454-61, 2009. ,
MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer, Nature, vol.515, pp.558-62, 2014. ,
Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial, Lancet, vol.387, pp.1909-1929, 2016. ,
Pembrolizumab as second-line therapy for advanced Urothelial carcinoma, N Engl J Med, vol.376, pp.1015-1041, 2017. ,
Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial, Lancet Oncol, vol.18, pp.312-334, 2017. ,
Updated efficacy and tolerability of durvalumab in locally advanced or metastatic urothelial carcinoma (UC), J Clin Oncol, vol.35, p.4525, 2017. ,
Avelumab in patients with metastatic urothelial carcinoma: pooled results from two cohorts of the phase 1b JAVELIN solid tumor trial, J Clin Oncol, vol.35, p.330, 2017. ,
Targeting the genetic alterations of the PI3K-AKT-mTOR pathway: its potential use in the treatment of bladder cancers, Pharmacol Ther, vol.145, pp.1-18, 2015. ,
Rapamycin inhibits in vitro growth and release of angiogenetic factors in human bladder cancer, Urology, vol.73, pp.665-674, 2009. ,
mTOR inhibitors show promising in vitro activity in bladder cancer and head and neck squamous cell carcinoma, Oncol Rep, vol.25, pp.763-771, 2011. ,
Inhibition of mammalian target of rapamycin as a therapeutic strategy in the management of bladder cancer, Cancer Biol Ther, vol.8, pp.2339-2386, 2009. ,
In vivo and in vitro effects of RAD001 on bladder cancer, Urol Oncol, vol.31, pp.1212-1233, 2013. ,
Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial, Lancet, vol.381, pp.125-157, 2013. ,
Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma, J Clin Oncol, vol.32, pp.760-767, 2014. ,
Randomized phase III trial of temsirolimus and bevacizumab versus interferon alfa and bevacizumab in metastatic renal cell carcinoma: INTORACT trial, J Clin Oncol, vol.32, pp.752-761, 2014. ,
Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer, N Engl J Med, vol.366, pp.520-529, 2012. ,
Everolimus for advanced pancreatic neuroendocrine tumors, N Engl J Med, vol.364, pp.514-537, 2011. ,
Phase II study of everolimus in patients with locally advanced or metastatic transitional cell carcinoma of the urothelial tract: clinical activity, molecular response, and biomarkers, Ann Oncol, vol.23, pp.2663-70, 2012. ,
Phase II study of everolimus in metastatic urothelial cancer, BJU Int, vol.112, pp.462-70, 2013. ,
Prevalence and co-occurrence of actionable genomic alterations in highgrade bladder cancer, J Clin Oncol, vol.31, pp.3133-3173, 2013. ,
A phase II trial of temsirolimus in second-line metastatic urothelial cancer, Med Oncol, vol.29, pp.2870-2876, 2012. ,
Safety and efficacy of temsirolimus as second-line treatment for patients with recurrent bladder cancer, J Clin Oncol, vol.33, issue.7, p.304, 2015. ,
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1), Eur J Cancer, vol.45, pp.228-275, 2009. ,
Optimal two-stage designs for phase II clinical trials, Control Clin Trials, vol.10, pp.1-10, 1989. ,
Sample size tables for clinical studies, 2009. ,
Role in bladder cancer prognosis and targeted therapeutics, PLoS One, vol.10, p.141253, 2015. ,
A randomized phase II/III study of cabazitaxel versus vinflunine in metastatic or locally advanced transitional cell carcinoma of the urothelium (SECAVIN), Ann Oncol, vol.28, pp.1517-1539, 2017. ,
Phase II study of dual phosphoinositol-3-kinase (PI3K) and mammalian target of rapamycin (mTOR) inhibitor BEZ235 in patients with locally advanced or metastatic transitional cell carcinoma, BJU Int, vol.118, pp.408-423, 2016. ,
Genome sequencing identifies a basis for everolimus sensitivity, Science, vol.338, p.221, 2012. ,
Comparing RECIST with EORTC criteria in metastatic bladder cancer, J Cancer Res Clin Oncol, vol.142, pp.187-94, 2016. ,
Systemic immunotherapy for Urothelial cancer: current trends and future directions, Cancers, vol.9, p.15, 2017. ,
Combining immunotherapy and targeted therapies in cancer treatment, Nat Rev Cancer, vol.12, pp.237-51, 2012. ,
Differential mTOR pathway profiles in bladder cancer cell line subtypes to predict sensitivity to mTOR inhibition, Urol Oncol, vol.35, pp.593-602, 2017. ,